Quarterly ResultMay 13, 2026, 04:18 PM
Acrivon Therapeutics Q1 Net Loss $(19.0)M; EPS $(0.49)
AI Summary
Acrivon Therapeutics reported a net loss of $19.0 million, or $(0.49) per share, for the first quarter of 2026, an improvement from the $19.7 million loss in the prior year. Total operating expenses decreased to $19.9 million. The company provided positive updates on its clinical-stage assets, ACR-368 and ACR-2316, with promising data from ongoing trials. As of March 31, 2026, cash, cash equivalents, and investments stood at $97.7 million, and the company expects its current funds, supplemented by $7.3 million from an April 2026 ATM program, to cover operating expenses for at least 12 months.
Key Highlights
- Net loss for Q1 2026 was $19.0 million, an improvement from $19.7 million in Q1 2025.
- Diluted net loss per share improved to $(0.49) in Q1 2026 from $(0.51) in Q1 2025.
- Total operating expenses decreased to $19.9 million in Q1 2026 from $21.7 million in Q1 2025.
- Cash, cash equivalents, and investments totaled $97.7 million as of March 31, 2026.
- Existing funds plus $7.3 million from April 2026 ATM program are expected to fund operations for at least 12 months.
- ACR-368 Phase 2b trial showed a 52% cORR in OncoSignature-positive serous endometrial cancer subjects.
- ACR-2316 Phase 1/2 trial demonstrated clinical activity in small cell lung cancer and squamous non-small cell lung cancer.
- All pre-funded warrants from the April 2024 PIPE were exercised during Q1 2026.
Price Impact
More from ACRV